Ashwagandha's Risks Outweigh Benefits as Germany's Supplement Market Grows Unchecked

Ashwagandha supplements remain popular in Germany despite growing safety concerns. While some small studies hint at benefits like reduced stress and better sleep, regulators warn of potential risks. A recent market analysis found many products exceed recommended dosage limits, raising questions about oversight and consumer protection. In Germany, ashwagandha is widely sold as a dietary supplement, claimed to balance stress, lower cortisol, and boost metabolism. However, there is little solid evidence to back these benefits. The most studied compounds in the herb, called withanolides, have shown anti-tumor effects in lab experiments—but only in cell cultures, not in human trials.

Small studies suggest ashwagandha may help with stress and anxiety when taken for six to eight weeks. Sleep quality might also improve at daily doses of 600 mg or more over at least eight weeks. Yet higher doses bring risks, including nausea, dizziness, headaches, and even liver damage. Germany currently has no legal maximum dosage for ashwagandha supplements. A 2026 market review revealed some products contain up to 6,000 mg per day—double the limit set in Poland. One supplement’s withanolide content was 15 times the recommended maximum. Dutch authorities have already linked 12 cases of liver damage to an ashwagandha-containing product. Regulation in Germany is minimal. Supplements only need registration with the Federal Office of Consumer Protection and Food Safety, which does not test for safety or effectiveness. The Federal Institute for Risk Assessment and other European bodies advise against ashwagandha use, especially for pregnant women, breastfeeding mothers, and children.

Ashwagandha supplements remain unregulated in Germany, despite warnings from health authorities. Some products far exceed dosage guidelines, increasing the risk of side effects. Without stricter controls, consumers face uncertainty about both safety and potential benefits.